A novel protective role for activating transcription factor 3 in the cardiac response to metabolic stress.

A. Ghigo,G. Frati,S. Sciarretta
DOI: https://doi.org/10.1093/cvr/cvw252
IF: 13.081
2017-02-01
Cardiovascular Research
Abstract:This editorial refers to ‘ATF3 expression in cardiomyocytes preserves homeostasis in the heart and controls peripheral glucose tolerance’ by R. Kalfon et al ., pp. 134–146. Type 2 diabetes mellitus (T2D) can promote the development of a specific form of cardiomyopathy independent of coronary artery disease and hypertension. This is the so-called diabetic cardiomyopathy, which represents a major cause of heart failure in Western countries.1 Unfortunately, the molecular mechanisms underlying the pathogenesis of diabetic cardiomyopathy still need to be elucidated. Similarly, the molecular and metabolic pathways mediating the cardiac response to diabetes-associated metabolic derangements are still elusive.1 The article by Kalfon et al. 2 significantly extends our current knowledge regarding the signalling pathways that are modulated in the heart in response to diabetes. They identified activating transcription factor 3 (ATF3) as a critical sensor of the metabolic stress associated with T2D in cardiomyocytes. ATF3 was found to protect the heart against T2D-induced cardiac remodelling and dysfunction, also controlling peripheral insulin sensitivity. ATF3 is an immediate early transcription factor of the basic leucine zipper (bZIP) superfamily, whose expression is generally low in physiological conditions. However, it is up-regulated by multiple stressors, including those that are involved in T2D cardiomyopathy, such as metabolic, oxidative, and endoplasmic reticulum stress, as well as inflammation.3 ATF3 functions by binding to the cyclic AMP response element (CRE) and, in turn, modulates the expression of multiple target genes including pro-inflammatory cytokines and …
What problem does this paper attempt to address?